Equity Brief · Healthcare2026-05-20
IQV·Healthcare

IQVIA Holdings Inc

I · AI Analysis

The brief

IQVIA provides three core services to life sciences companies: (1) Technology & Analytics Solutions — cloud platforms and data on drug sales, prescribing trends, and patient outcomes across global markets; (2) Research & Development Solutions — clinical trial management, patient recruitment, laboratory services, and genomic testing; (3) Contract Sales & Medical Solutions — outsourced sales teams and patient engagement services for pharmaceutical companies [Yahoo Finance]. Think of them as the company that helps drug makers figure out which medicines are selling where, run clinical trials faster, and get products to market more efficiently.

IQVIA Holdings is a $28.1B healthcare data and clinical research company serving pharmaceutical and biotech clients globally [Yahoo Finance]. The company combines cloud-based analytics, real-world evidence platforms, and clinical trial services — essentially acting as the infrastructure backbone for drug development and commercialization. Recent news highlights strong Q1 earnings, an expanded AI-powered biosimilar partnership with Kexing Biopharm, and growing demand for its data analytics tools [Yahoo Finance].

IQVIA shows solid profitability and cash generation, but carries elevated debt that keeps the overall health score moderate.

The brief AI analysisConfidence 7/10

Sentinellis health

5.8/10

Moderate concerns

Market capitalisation

$28.1B

Revenue (TTM)

$16.3B

Explainers

How we read these numbers

Plain-English guides · no account needed

II · Recent news

What moved

5 stories · ranked by relevance

  • Macro2026-05-18

    IQVIA (IQV) Fell Despite Strong Fundamentals

    Yahoo Finance

  • Macro2026-05-15

    IQVIA’s Q1 Earnings Call: Our Top 5 Analyst Questions

    Yahoo Finance

  • Macro2026-05-13

    IQVIA and Kexing Biopharm Expand Strategic Collaboration to Accelerate Global Biosimilar Development using AI-Enabled Capabilities

    Yahoo Finance

  • Macro2026-05-15

    Will IQVIA's (IQV) AI‑Driven Biosimilar Partnership with Kexing Reshape Its Long‑Term Narrative?

    Yahoo Finance

  • Macro2026-05-17

    Repligen, AdaptHealth, and IQVIA Stocks Trade Down, What You Need To Know

    Yahoo Finance

Premium · Free with any account

IQVIA carries net debt at 4.1x EBITDA, meaningfully above the 3x comfort threshold — this limits financial flexibility and increases vulnerability if revenue slows or interest rates rise [Yahoo Finance].

1 of 4 risks in this report

Risks

4

Opportunities

6

Red flags

3

Leadership

10

12 more findings in the full report — free with any account.

Unlock the full IQVIA Holdings Inc analysis

Create a free account to access the complete AI-generated report with inline citations.

  • 4 risks, 6 opportunities and 3 red flags — each with its source
  • 100+ financial metrics with charts and benchmarks
  • Full news summaries with source links
  • Executive team and compensation details
  • PDF export for offline use
Unlock all 13 findings3 free reports · No credit card

III · Related

You might also read

Same sector · Healthcare — or comparable health

Want this for your watchlist?

Read three companies free. No card.

Get 3 free reports

Produced 20 May 2026, 19:55 UTC

Figures come from company filings and market data. The Sentinellis health score and the wording attached to it are our interpretation of those figures, not numbers the company reported.

Not investment advice and not a recommendation to buy or sell. Sentinellis holds no positions in the companies it covers, takes no payment from issuers, and has no broker referral arrangements.

How every figure and score is calculated